"Our focus on innovative product development remains strong, and we are committed to investing in R&D to ensure we remain at the forefront of the life sciences tools market."
— John Doe, CEO
03Detailed Report
MLAB
Mesa Laboratories Inc
Period
Q4 2024
CurrencyUSD
Report TypeQuarterly Earnings
GeneratedJun 25, 2026
Swipe to view all report sections
Executive Summary
Mesa Laboratories Inc (MLAB) reported mixed results for Q4 2024, with total revenues of $58.9 million, marking a year-over-year increase of 5.96% and a 10.16% rise compared to the previous quarter. Despite these gains, the company faced significant challenges, posting a net loss of $254.6 million, which reflects a staggering decline in profitability with a net income ratio of -4.32% and a diluted EPS of -$47.20. Management reiterated their commitment to streamlining operations and enhancing product offerings, while also navigating ongoing market challenges. Investors should closely monitor the company’s strategic initiatives aimed at improving profitability and market positioning.
Key Performance Indicators
Revenue
Increasing
58.90M
QoQ: 10.16% | YoY: 5.96%
Gross Profit
Decreasing
31.08M
52.76% margin
QoQ: -6.96% | YoY: -6.39%
Operating Income
Increasing
3.25M
QoQ: 4 949.25% | YoY: 138.05%
Net Income
Decreasing
-254.58M
QoQ: -12 131.33% | YoY: -41 766.61%
EPS
Decreasing
-47.20
QoQ: -12 202.56% | YoY: -43 009.09%
Revenue Trend
Margin Analysis
Financial Highlights
1. Revenue Performance:
- Revenue of $58.9 million, up 5.96% YoY and down from $59.5 million in Q3 2024.
- Cost of revenue recorded at $27.8 million, leading to a gross profit of $31.1 million, but the gross profit margin decreased to 52.76%.
2. Profitability Metrics:
- Operating income improved significantly at $3.2 million (Operating income Ratio: 5.52%), a massive increase compared to a loss of $670,000 in Q3 2024 but overshadowed by escalating losses due to other expenses.
- The company reported a net income of -$254.6 million, reflecting a drastic 41,766.61% decline in profitability YoY.
- The EBITDA loss was $267.1 million, indicating operational inefficiencies.
3. Balance Sheet and Cash Flow:
- Cash and cash equivalents at period-end are $28.2 million, slightly decreased from $28.4 million at the start of the period.
- Despite a negative net income, net cash provided by operating activities was positive at $12.9 million, suggesting strong operational cash flow generation from core activities.
Income Statement
Metric
Value
YoY Change
QoQ Change
Revenue
58.90M
5.96%
10.16%
Gross Profit
31.08M
-6.39%
-6.96%
Operating Income
3.25M
138.05%
4 949.25%
Net Income
-254.58M
-41 766.61%
-12 131.33%
EPS
-47.20
-43 009.09%
-12 202.56%
Key Financial Ratios
Gross Profit Margin
Good
52.80%
Gross profit margin is healthy and competitive within industry standards
Operating Profit Margin
Fair
5.52%
Operating margin is moderate, room for improvement in cost management
Net Profit Margin
Weak
-4.32%
Net profit margin is below industry norms, profitability concerns
Return on Assets
Weak
-0.57%
Return on assets suggests inefficient capital allocation
Return on Equity
Weak
-1.75%
Return on equity suggests inefficient capital allocation
Current Ratio
Healthy
2.47
Current ratio shows adequate liquidity to meet short-term obligations
Debt to Equity
High Risk
1.59
Debt-to-equity indicates high leverage and elevated financial risk
P/E Ratio
Negative
-0.59x
Negative earnings make P/E ratio not meaningful
Price to Book
Premium
4.16x
Trading at premium to book value, reflects strong intangibles or growth
Management Insights Available for Members
Get exclusive access to management commentary, earnings call quotes, and forward guidance from company leadership.